Pharmacokinetics of peramivir after single intravenous doses in healthy Chinese subjects

Xenobiotica

Volumn 45, Issue 3, 2015, Pages 239-243

  Zhang, Dan ^a   Du, Aihua ^a   Zhang, Lina ^a   Ma, Jingyi ^a   Meng, Lingjie ^a   Deng, Ming ^a   Xu, Juan ^a   Liu, Huichen ^a  

^a AEROSPACE CENTER HOSPITAL   (China)

Author keywords

Chinese subjects; Intravenous infusion; Peramivir; Pharmacokinetics; Plasma; Urine

Indexed keywords

FIBRINOGEN; HEMOGLOBIN; PERAMIVIR; SODIUM CHLORIDE; CYCLOPENTANE DERIVATIVE; GUANIDINE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CHINESE; DRUG BLOOD LEVEL; DRUG INFUSION; DRUG SAFETY; ELIMINATION HALF-LIFE; ELIMINATION RATE CONSTANT; FEMALE; FIBRINOGEN BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; KIDNEY CONCENTRATING CAPACITY; LIQUID CHROMATOGRAPHY; LYMPHOCYTOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NORMAL HUMAN; OPEN STUDY; PLASMA CONCENTRATION-TIME CURVE; SIDE EFFECT; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; THROMBIN TIME; URINALYSIS; URINARY EXCRETION; VEIN PUNCTURE; VOLUME OF DISTRIBUTION; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; CHEMISTRY; CHINA; CONTROLLED STUDY; DEMOGRAPHY; DOSE RESPONSE; INTRAVENOUS DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT;

ADMINISTRATION, INTRAVENOUS; ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; CYCLOPENTANES; DEMOGRAPHY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GUANIDINES; HEALTHY VOLUNTEERS; HUMANS; MALE; YOUNG ADULT;

EID: 84923935899     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2014.960907     Document Type: Article

References (16)

1. Babu YS, Chand P, Bantia S, et al. (2000). BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. J Med Chem 43:3482-6.
2. Bantia S, Arnold CS, Parker CD, et al. (2006). Anti-influenza virus activity of peramivir in mice with single intramuscular injection. Antiviral Res 69:39-45.
3. Birnkrant D, Cox E. (2009). The Emergency Use Authorization of peramivir for treatment of 2009 H1N1 influenza. N Engl J Med 361: 2204-7
4. EMA. (2011). Guideline on bioanalytical method validation. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2011/08/WC500109686.pdf [last accessed 22 Oct 2012].
5. Gough K, Hutchison M, Keene O, et al. (1995). Assessment of dose proportionality: report from the statisticians in the pharmaceutical industry/pharmacokinetics UK joint working party. Drug Inf J 29: 1039-48.
6. Gubareva LV, Webster RG, Hayden FG. (2001). Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants. Antimicrob Agents Chemother 45:3403-8.
7. Health Canada. (2012). Guidance document, conduct and analysis of comparative bioavailability studies. Available from: http://www.hcsc. gc.ca/dhp-mps/alt-formats/pdf/prodpharma/applic-demande/guideld/bio/gd-cbs-ebc-ld-eng.pdf [last accessed 16 Apr 2014].
8. Kiso M, Mitamura K, Sakai-Tagawa Y, et al. (2004). Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 364:759-65.
9. Kohno S, Yen MY, Cheong HJ, et al. (2011). Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir inpatients with seasonal influenza virus infection. Antimicrob Agents Chemother 55:5267-76. Pharmaceuticals and
10. Medical Devices Agency (PMDA). 2013,RAPIACTA for Intravenous drip infusion, Available from:http://www.info.pmda.go.jp/go/pack/6250405A1032102 [last accessed 30 Jun 2014].
11. Smith BP, Vandenhende FR, DeSante KA, et al. (2000). Confidence interval criteria for assessment of dose proportionality. Pharm Res 17: 1278-83.
12. Sorbello A, Jones SC, Carter W, et al. (2012). Emergency use authorization for intravenous peramivir: evaluation of safety in the treatment of hospitalized patients infected with 2009 H1N1 influenza A virus. Clin Infect Dis 55:1-7.
13. Sugaya N, Kohno S, Ishibashi T, et al. (2012). Efficacy, safety, and pharmacokinetics of intravenous peramivir in children with 2009 pandemic H1N1 influenza A virus infection. Antimicrob Agents Chemother 56:369-77.
14. Swan S, Marbury T, Smith W, et al. (2009). Safety and pharmacokinetics of peramivir following intravenous administration in subjects with renal impairment. Available from: http://www.biocryst.com/PDFs/BCRX-Peramivir-Swan-IDSA-2009-Poster.pdf [last accessed 30 Jun 2014].
15. US FDA. (2001). Guidance for industry, bioanalytical method validation. Available from: http://www.fda.gov/downloads/Drugs/Guidance ComplianceRegulatoryInformation/Guidances/ucm070107.pdf [last accessed 3 Jul 2008].
16. US FDA. (2009). Emergency use authorization of peramivir IV, fact sheet for health care providers. Available from: http://www.fda.gov/downloads/drugs/drugsafety/postmarketdrugsafetyinformationfor patientsandproviders/ucm187811.pdf [last accessed 12 Aug 2014].